IMC Form F1 - US Registration Statement (Prelim. Prospectus)
Filed with ASX · · 200 pages · English
We are offering 416,667 American Depositary Shares (each, an “ADS” and, collectively the “ADSs”) and warrants to purchase 208,334 ADSs (each a “Warrant” and, collectively the“Warrants”) at an offering price of $21.00 per ADS and $.01 per Warrant. Each ADS will represent forty (40) of our ordinary shares. Each Warrant will have an estimated per ADS exercise price of 125% of the per ADS public offer
In the deck
Earlier from Immuron
- Positive Results of IMM-124E in Acute Colitis Studies
- Close of Recruitment of Phase II NASH Trial
- Appendix 4D - Half Year Report and Accounts - Dec 2016
- Immuron Completes Phase II NASH Clinical Trial Recruitment
- First Patient in Pediatric Fatty-Liver Phase II Trial
Later from Immuron
- Completion of Manufacturing of Drug Product for C-Diff Trial
- IMC Expands Agreement with US Army-3 Additional Therapeutics
- NASDAQ Listing on Hold Pending NASH Interim Analysis Results
- Immuron Secures $1.5M R&D Cash Advance Loan Funding
- Travelan Increases Industry Presence - Conf & Sales Update
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron